Drug Profile
Renal cancer vaccine - Lumos Pharma
Alternative Names: HyperAcute™ Renal; Renal immunotherapy - Lumos PharmaLatest Information Update: 14 Apr 2022
Price :
$50
*
At a glance
- Originator NewLink Genetics Corporation
- Developer Lumos Pharma
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal cancer
Most Recent Events
- 12 Jan 2021 NewLink Genetics completes a phase I trial in Renal cancer (Metastatic disease, Second-line therapy or greater) in USA (Intradermal, Injection) (NCT02035358)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Renal-cancer (Metastatic disease) in USA (Intradermal, Injection)
- 01 Dec 2013 Preclinical trials in metastatic Renal cancer in USA (Intradermal)